As well as the IPF candidate, the merger gave Aileron a phase-2b-ready treatment for loculated pleural effusions and a cystic fibrosis program. Finding funding for the programs remains an issue.

In this article, we will describe the current status of personalized medicine for chronic, complex diseases using chronic obstructive pulmonary ... medicine to the bedside Although the promise ...

POCUS has become a portable innovation across different corners of medicine — a tool valued for not only its bedside ... ultrasound skills were pivotal when conducting daily volume assessments in the ...